Treatment Set TS350565 is a Intradermal; Subcutaneous Injection, Solution in the Non-standardized Allergenic category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Dermatophagoides Pteronyssinus; Cochliobolus Sativus; Penicillium Chrysogenum Var. Chrysogenum.
| Product ID | 49288-0938_6e25c8e0-c526-446a-ae3c-33c3078f6714 |
| NDC | 49288-0938 |
| Product Type | Non-standardized Allergenic |
| Proprietary Name | Treatment Set TS350565 |
| Generic Name | Treatment Set Ts350565 |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRADERMAL; SUBCUTANEOUS |
| Marketing Start Date | 1986-10-31 |
| Marketing Category | BLA / BLA |
| Application Number | BLA102223 |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | DERMATOPHAGOIDES PTERONYSSINUS; COCHLIOBOLUS SATIVUS; PENICILLIUM CHRYSOGENUM VAR. CHRYSOGENUM |
| Active Ingredient Strength | 400 [AU]/mL; g/mL; g/mL |
| Pharm Classes | Standardized Insect Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Antigens, Dermatophagoides [CS],Insect Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2017-12-31 |
| Marketing Start Date | 1986-10-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA102223 |
| Product Type | NON-STANDARDIZED ALLERGENIC |
| Marketing Start Date | 1986-10-31 |
| Inactivation Date | 2019-11-27 |
| Ingredient | Strength |
|---|---|
| DERMATOPHAGOIDES PTERONYSSINUS | 400 [AU]/mL |